长春高新：关于子公司吸附无细胞百（二组分）白破联合疫苗（成人及青少年用）临床试验申请获得批准的公告

Core Points - Changchun High-tech announced that its subsidiary, Changchun Baike Biotechnology Co., has received the clinical trial approval notice from the National Medical Products Administration for its adsorbed acellular combined vaccine for adults and adolescents [1] Group 1 - The company has made significant progress in vaccine development with the approval of a clinical trial for a new vaccine [1]